Candel’s CAN-2409 Shows Long-Term Survival Benefit in Pancreatic Cancer Trial

Candel Therapeutics has revealed groundbreaking final data from its Phase 2 trial, demonstrating that its investigational therapy, CAN-2409, could be a game-changer for patients with borderline resectable pancreatic cancer (PDAC). In combination with standard chemoradiation and surgery, CAN-2409 extended survival significantly, with some patients living well beyond five years post-treatment. Unlike those on standard treatment alone, long-term survivors in the CAN-2409 group responded positively to salvage chemotherapy even after disease recurrence, highlighting the therapy’s potential to keep cancer at bay longer.

Dr. W. Garrett Nichols, Candel’s Chief Medical Officer, emphasized the urgent need for better treatment options, as pancreatic cancer remains one of the deadliest malignancies. CAN-2409, designed to turn a patient’s tumor into a personalized vaccine, could redefine treatment by enhancing immune response and extending life expectancy. With these promising results, the therapy brings fresh hope to patients facing a disease known for its relentless progression and poor prognosis.